Teva Stock: Sustained Revenue Growth Amid Financial Strain (NYSE:TEVA)

Date:


Woman pulling vibrant red rope from tangle

Klaus Vedfelt

Teva’s Q1 2024 Earnings Highlight Growth Amid Challenges

Teva’s (NYSE:TEVA) stock is up 55% since I called for a “2024 revival” in December. Back then, I was confident that their blockbuster drugs (such as Austedo, Ajovy, and Uzedy) would continue to add



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related